Clinical Trials

37 enrolled

Salivary Gland Neoplasms

NCT05075980 2026-04-13

Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study

174 enrolled

Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Lymphatic Metastasis, Mouth Neoplasms, Oropharyngeal Neoplasms, Paranasal Sinus Neoplasms, Salivary Gland Neoplasms

NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

200 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Phase 2 Completed

57 enrolled

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT05408845 2026-04-03

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

146 enrolled

Salivary Gland Neoplasms

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

39 enrolled

Salivary Gland Neoplasms

NCT05884320 2026-03-20

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

30 enrolled

Salivary Gland Neoplasms

NCT03360890 2026-03-13

iPRIME

46 enrolled

Salivary Gland Neoplasms, Thyroid Neoplasms

NCT00939627 2026-03-10

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

Phase 2 Completed

55 enrolled 10 charts

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT02568267 2026-03-06

STARTRK-2

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

534 enrolled 1 FDA

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT04895735 2026-02-02

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

45 enrolled